For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies.

A new study on circulating tumor DNA (ctDNA) testing for advanced breast cancer has unveiled encouraging results, with high ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...

Different sociodemographic groups, especially racial and ethnic minorities, are less likely to receive timely breast cancer diagnostic services after an abnormal screening mammogram, according to a ...

BAGUIO CITY (PIA) – The Baguio City Health Services Office (CHSO) emphasized the importance of cancer screening for early detection for higher possibility of getting treated or delay the progression ...

Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.

Vimentin is a type III intermediate filament (IF) protein typically expressed in cells that differentiate into connective ...

Researchers have identified a key role microglia play in melanoma brain metastases progression and mechanisms to target them.